Taken together, our results highlight the critical impact of KEAP1/NRF2 signaling in the response to immunotherapy in melanoma, one of the most highly immunotherapy responsive cancers, together with the contribution of intrinsic heterogeneity in fundamental homeostatic cellular pathways that modulate such therapeutic responses. Here, NFE2L2 is linked to cancer.